This topic contains a solution. Click here to go to the answer

Author Question: The process by which a medication passing through the liver may be partially or completely ... (Read 132 times)

iveyjurea

  • Hero Member
  • *****
  • Posts: 555
The process by which a medication passing through the liver may be partially or completely inactivate many medications is known as:
 
  a. First-pass effect
  b. Prodrug effect
  c. Protein reservoir binding
  d. Plasma binding effect

Question 2

The heart is protected anteriorly by the:
 
  a. mediastinum.
  b. sternum.
  c. spinal column.
  d. 5th and 6th ribs.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

hugthug12

  • Sr. Member
  • ****
  • Posts: 329
Answer to Question 1

a
Rationale: a. Correct.
b. A prodrug is an inactive precursor of a drug prior to conversion to an active metabolite.
c. Protein reservoir binding occurs when a portion of a drug is bound to proteins but may be released for us at a later time.
d. Plasma binding occurs with proteins as described above in answer c.

Answer to Question 2

B





 

Did you know?

In women, pharmacodynamic differences include increased sensitivity to (and increased effectiveness of) beta-blockers, opioids, selective serotonin reuptake inhibitors, and typical antipsychotics.

Did you know?

This year, an estimated 1.4 million Americans will have a new or recurrent heart attack.

Did you know?

Parkinson's disease is both chronic and progressive. This means that it persists over a long period of time and that its symptoms grow worse over time.

Did you know?

The Centers for Disease Control and Prevention (CDC) was originally known as the Communicable Disease Center, which was formed to fight malaria. It was originally headquartered in Atlanta, Georgia, since the Southern states faced the worst threat from malaria.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library